Hood River Capital Management LLC lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 2.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 121,390 shares of the biopharmaceutical company’s stock after buying an additional 2,546 shares during the quarter. Hood River Capital Management LLC owned about 0.25% of Agios Pharmaceuticals worth $8,103,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. QS Investors LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter worth about $144,000. Teacher Retirement System of Texas bought a new stake in Agios Pharmaceuticals during the 3rd quarter valued at approximately $225,000. S&CO Inc. bought a new stake in Agios Pharmaceuticals during the 3rd quarter valued at approximately $227,000. Cubist Systematic Strategies LLC raised its stake in Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares during the period. Finally, C WorldWide Group Holding A S raised its stake in Agios Pharmaceuticals by 137.5% during the 3rd quarter. C WorldWide Group Holding A S now owns 3,800 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 2,200 shares during the period. 93.16% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Hood River Capital Management LLC Buys 2,546 Shares of Agios Pharmaceuticals, Inc. (AGIO)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/17/hood-river-capital-management-llc-buys-2546-shares-of-agios-pharmaceuticals-inc-agio.html.
In other news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total value of $227,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 182,908 shares of company stock valued at $12,391,239. Company insiders own 10.55% of the company’s stock.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up $0.56 during midday trading on Friday, reaching $59.63. The company’s stock had a trading volume of 469,700 shares, compared to its average volume of 528,150. Agios Pharmaceuticals, Inc. has a fifty-two week low of $39.24 and a fifty-two week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.63) EPS. equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.
Several analysts recently issued reports on AGIO shares. BidaskClub downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. set a $83.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price on the stock. J P Morgan Chase & Co reissued a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $75.70.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.